Elucidating the role of B cell mediated trans infection in the establishment of the latent HIV-1 reservoir

阐明 B 细胞介导的反式感染在潜伏 HIV-1 病毒库建立中的作用

基本信息

项目摘要

SUMMARY HIV-1 can proliferate through both the release of cell-free particles (cis-infection) and by cell-to-cell transmission (trans-infection). Prior studies have shown that HIV-1 trans-infection: (i) is significantly more efficient than cis-infection; (ii) can efficiently infect resting CD4+ T cells, which are inherently resistant to cis- infection; and (iii) is largely insensitive to inhibition by antiretroviral therapy (ART). Consequently, HIV-1 trans- infection is thought to play a key role in the pathogenesis of HIV-1 infection. Direct evidence of HIV-1 trans- infection in vivo, however, is lacking! Our group was the first to demonstrate that activated B cells express the C-type lectin DC-SIGN and have the ability to sequester and then efficiently transfer HIV-1 to bystander CD4+T cells. B cells have a greater capacity to transfer HIV-1 to CD4+ T cells than other antigen presenting cells, including dendritic cells (DCs) and macrophages. We recently found that B cells, but not immature or mature DC, also have the unique ability to efficiently trans-infect CD4+ naïve (TN) cells – which do not express the CCR5 receptor – with R5-tropic HIV-1. Importantly, we have reported that B cells from HIV-infected nonprogressors (NPs, individuals who control viremia in the absence of ART) do not support HIV-1 trans- infection of CD4+ T cells. Consistent with these findings, purified CD4+ TN cells isolated from NPs harbor a very small (or even negligible) reservoir of total HIV-1 DNA, compared to ART-treated progressors. In this R01 application, our overarching hypothesis is that B lymphocyte-mediated cell-to-cell HIV-1 trans-infection contributes to the establishment and replenishment of the latent viral reservoir in resting CD4+ T cells, in particular CD4+ TN and T follicular helper cells. We propose to use novel state-of the-art approaches to investigate this hypothesis, and expect to provide the first evidence that HIV-1 trans-infection plays a key role in viral pathogenesis.
总结 HIV-1可以通过释放无细胞颗粒(顺式感染)和通过细胞与细胞之间的相互作用来增殖。 传播(transinfection)。先前的研究表明,HIV-1的跨感染:(i)明显高于 比顺式感染更有效;(ii)可以有效地感染静息的CD 4 + T细胞,这些细胞固有地对顺式感染具有抗性。 感染;和(iii)很大程度上对抗逆转录病毒疗法(ART)的抑制不敏感。因此,HIV-1反式- 感染被认为在HIV-1感染的发病机制中起关键作用。HIV-1反式病毒的直接证据 然而,缺乏体内感染!我们的小组是第一个证明活化的B细胞表达 C型凝集素DC-SIGN具有隔离HIV-1并将其有效转移给旁观者的能力 CD 4 +T细胞。B细胞比其他抗原呈递细胞具有更大的将HIV-1转移到CD 4 + T细胞的能力 细胞,包括树突状细胞(DC)和巨噬细胞。我们最近发现,B细胞,但不是不成熟或 成熟的DC也具有有效地反式感染CD 4+幼稚(TN)细胞的独特能力,所述TN细胞不表达 CCR 5受体-与R5嗜性HIV-1。重要的是,我们已经报道了来自HIV感染者的B细胞 非进展者(NP,在没有ART的情况下控制病毒血症的个体)不支持HIV-1转基因, 感染CD 4 + T细胞。与这些发现一致,从NPs中分离的纯化的CD 4 + TN细胞具有 与ART治疗的进展者相比,HIV-1总DNA的储存量非常小(甚至可以忽略不计)。在此R 01 应用中,我们的首要假设是B淋巴细胞介导的细胞间HIV-1反式感染 有助于在静息的CD 4 + T细胞中建立和补充潜伏病毒库, 特别是CD 4 + TN和T滤泡辅助细胞。我们建议使用新的最先进的方法, 研究这一假设,并期望提供第一个证据表明,HIV-1的反式感染发挥了关键作用, 病毒发病机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NICOLAS PAUL SLUIS-CREMER其他文献

NICOLAS PAUL SLUIS-CREMER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NICOLAS PAUL SLUIS-CREMER', 18)}}的其他基金

Elucidating the role of B cell mediated trans infection in the establishment of the latent HIV-1 reservoir
阐明 B 细胞介导的反式感染在潜伏 HIV-1 病毒库建立中的作用
  • 批准号:
    10402053
  • 财政年份:
    2022
  • 资助金额:
    $ 72.85万
  • 项目类别:
Potent inhibition of HIV-1 latency reversal by PF 03758309
PF 03758309 有效抑制 HIV-1 潜伏期逆转
  • 批准号:
    10409846
  • 财政年份:
    2021
  • 资助金额:
    $ 72.85万
  • 项目类别:
Potent inhibition of HIV-1 latency reversal by PF 03758309
PF 03758309 有效抑制 HIV-1 潜伏期逆转
  • 批准号:
    10326435
  • 财政年份:
    2021
  • 资助金额:
    $ 72.85万
  • 项目类别:
The "Kick" Revisited in the "Kick and Kill" Strategy
“踢杀”策略中的“踢”重温
  • 批准号:
    9301475
  • 财政年份:
    2016
  • 资助金额:
    $ 72.85万
  • 项目类别:
The "Kick" Revisited in the "Kick and Kill" Strategy
“踢杀”策略中的“踢”重温
  • 批准号:
    9016996
  • 财政年份:
    2016
  • 资助金额:
    $ 72.85万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    8143220
  • 财政年份:
    2010
  • 资助金额:
    $ 72.85万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    9265402
  • 财政年份:
    2009
  • 资助金额:
    $ 72.85万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    7872929
  • 财政年份:
    2009
  • 资助金额:
    $ 72.85万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    8079113
  • 财政年份:
    2009
  • 资助金额:
    $ 72.85万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    8289671
  • 财政年份:
    2009
  • 资助金额:
    $ 72.85万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 72.85万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 72.85万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 72.85万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 72.85万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 72.85万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 72.85万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 72.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 72.85万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 72.85万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 72.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了